• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Pharmacovigilance: Boon for the safety and efficacy of Ayuvedic formulations.药物警戒:阿育吠陀制剂安全性和有效性的福音。
J Ayurveda Integr Med. 2010 Oct;1(4):251-6. doi: 10.4103/0975-9476.74427.
2
Contribution of world health organization in the global acceptance of Ayurveda.世界卫生组织在阿育吠陀全球认可度方面的贡献。
J Ayurveda Integr Med. 2011 Oct;2(4):179-86. doi: 10.4103/0975-9476.90769.
3
Government policies and initiatives for development of Ayurveda.政府发展阿育吠陀的政策和举措。
J Ethnopharmacol. 2017 Feb 2;197:25-31. doi: 10.1016/j.jep.2016.08.018. Epub 2016 Aug 16.
4
Pharmacovigilance study of Ayurvedic medicine in Ayurvedic Teaching Hospital: A prospective survey study.阿育吠陀教学医院中阿育吠陀医学的药物警戒研究:一项前瞻性调查研究。
Ayu. 2015 Apr-Jun;36(2):130-7. doi: 10.4103/0974-8520.175539.
5
Awareness, practice and views about integrating AYUSH in allopathic curriculum of allopathic doctors and interns in a tertiary care teaching hospital in New Delhi, India.印度新德里一家三级护理教学医院的西医医生和实习医生对将阿育吠陀整合到西医课程中的意识、实践和观点。
J Integr Med. 2018 Mar;16(2):113-119. doi: 10.1016/j.joim.2018.02.001. Epub 2018 Feb 5.
6
Changing scenario for promotion and development of Ayurveda--way forward.阿育吠陀的推广和发展的变化情况——前进的道路。
J Ethnopharmacol. 2012 Sep 28;143(2):424-34. doi: 10.1016/j.jep.2012.07.036. Epub 2012 Aug 2.
7
Regulatory Requirements for Quality Control of Unani Medicines.《维吾尔药质量控制的监管要求》。
J AOAC Int. 2020 Jun 1;103(3):634-648. doi: 10.5740/jaoacint.19-0285.
8
Safety monitoring of local anaesthetic drugs from the perspective of Pharmacovigilance Programme of India.从印度药物警戒计划的角度看局部麻醉药的安全性监测
Indian J Anaesth. 2017 Jul;61(7):534-537. doi: 10.4103/ija.IJA_418_17.
9
Ayurpharmacoepidemiology en Route to Safeguarding Safety and Efficacy of Ayurvedic Drugs in Global Outlook.阿育吠陀药物流行病学:在全球视野下保障阿育吠陀药物安全性与有效性的道路上
J Evid Based Complementary Altern Med. 2017 Apr;22(2):294-298. doi: 10.1177/2156587215624032. Epub 2016 Jun 22.
10
Mainstreaming of Ayurveda, Yoga, Naturopathy, Unani, Siddha, and Homeopathy with the health care delivery system in India.将阿育吠陀、瑜伽、顺势疗法、尤纳尼、悉达和顺势疗法纳入印度的医疗保健提供系统。
J Tradit Complement Med. 2015 Jan 7;5(2):116-8. doi: 10.1016/j.jtcme.2014.11.002. eCollection 2015 Apr.

引用本文的文献

1
Impact assessment of integrated-pathy on cancer-related fatigue in cancer patients: an observational study.整合路径对癌症患者癌因性疲乏影响的评价:一项观察性研究。
J Health Popul Nutr. 2024 Apr 4;43(1):48. doi: 10.1186/s41043-024-00537-z.
2
Ayurveda formulations: A roadmap to address the safety concerns.阿育吠陀配方:解决安全问题的路线图。
J Ayurveda Integr Med. 2017 Oct-Dec;8(4):279-282. doi: 10.1016/j.jaim.2017.08.010. Epub 2017 Nov 7.
3
Bridging Ayurveda with evidence-based scientific approaches in medicine.将阿育吠陀与循证医学方法相结合。
EPMA J. 2014 Nov 1;5(1):19. doi: 10.1186/1878-5085-5-19. eCollection 2014.
4
Adverse drug reaction and concepts of drug safety in Ayurveda: An overview.阿育吠陀医学中的药物不良反应与药物安全概念:概述
J Young Pharm. 2013 Dec;5(4):116-20. doi: 10.1016/j.jyp.2013.10.001. Epub 2013 Oct 23.
5
Adverse events attributed to traditional Korean medical practices: 1999-2010.归因于传统韩国医疗实践的不良事件:1999-2010 年。
Bull World Health Organ. 2013 Aug 1;91(8):569-75. doi: 10.2471/BLT.12.111609. Epub 2013 May 31.
6
Awareness about bibliographic databases among students of Ayurveda and qualified Ayurveda practitioners.阿育吠陀学生和合格的阿育吠陀从业者对书目数据库的认知。
J Ayurveda Integr Med. 2012 Apr;3(2):59-62. doi: 10.4103/0975-9476.96516.
7
Contribution of world health organization in the global acceptance of Ayurveda.世界卫生组织在阿育吠陀全球认可度方面的贡献。
J Ayurveda Integr Med. 2011 Oct;2(4):179-86. doi: 10.4103/0975-9476.90769.
8
Ayurveda GCP Guidelines: Need for freedom from RCT ascendancy in favor of whole system approach.阿育吠陀药物临床试验质量管理规范指南:摆脱随机对照试验主导地位转而支持整体系统方法的必要性。
J Ayurveda Integr Med. 2011 Jan;2(1):1-4. doi: 10.4103/0975-9476.78175.

本文引用的文献

1
Pharmacovigilance training with focus on India.聚焦印度的药物警戒培训。
Indian J Pharmacol. 2008 Feb;40(Suppl 1):S28-30.
2
Pharmacovigilance obligations of the pharmaceutical companies in India.印度制药公司的药物警戒义务。
Indian J Pharmacol. 2008 Feb;40(Suppl 1):S13-6.
3
Lead, mercury, and arsenic in US- and Indian-manufactured Ayurvedic medicines sold via the Internet.通过互联网销售的美国和印度制造的阿育吠陀药品中的铅、汞和砷。
JAMA. 2008 Aug 27;300(8):915-23. doi: 10.1001/jama.300.8.915.
4
Effect of gugulipid on bioavailability of diltiazem and propranolol.古古勒脂对地尔硫䓬和普萘洛尔生物利用度的影响。
J Assoc Physicians India. 1994 Jun;42(6):454-5.
5
Reporting systems for rare side effects of non-narcotic analgesics in India. Problems and opportunities.印度非麻醉性镇痛药罕见副作用报告系统。问题与机遇。
Med Toxicol. 1986;1 Suppl 1:110-3.

药物警戒:阿育吠陀制剂安全性和有效性的福音。

Pharmacovigilance: Boon for the safety and efficacy of Ayuvedic formulations.

作者信息

Chaudhary Anand, Singh Neetu, Kumar Neeraj

机构信息

Regional Pharmacovigilance Centre for Ayurvedic Drugs, North Zone.

出版信息

J Ayurveda Integr Med. 2010 Oct;1(4):251-6. doi: 10.4103/0975-9476.74427.

DOI:10.4103/0975-9476.74427
PMID:21731371
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3117316/
Abstract

Pharmacovigilance is a corrective process originating in pharmaco-epidemiology. The 1997 Erice Declaration, presented at the World Health Organisation, became the basis on which the concept was implemented internationally for conventional systems of medicine. The increasing international acceptance of Ayurveda, led regulators to implement a similar program for Ayurveda, particularly as some medical professionals, scientists and members of the public reported adverse reactions after taking Ayurvedic formulations. The World Health Organisation therefore persuaded the Department of AYUSH, Ministry of Health and Family Welfare, Government of India, to implement a pharmacovigilance program for Ayurveda, as a means to ensuring the safety and efficacy of Ayurvedic medicines. After a year of due diligence, the pharmacovigilance program was launched nationally on 29 September 2008. Since that time, Ayurveda, Siddha and Unani medicines have been monitored according to the provisions of a protocol prepared by the National Pharmacovigilance Resource Centre, IPGTRA, Jamnagar, and approved by Department of AYUSH. The program was reviewed, first, on 21st January 2009 by the National Pharmaco-vigilance Consultative Committee for ASU drugs (NPCC-ASU), and again, on 15 Feburary, 2010, when an evaluation meeting effectively rubber stamped the program. Among the outcomes of these meetings were several suggestions of measures to improve the program's efficiency. Recent developments include the constitution of pharmacovigilance centers at all Ayurveda Teaching institutes and research centers.

摘要

药物警戒是起源于药物流行病学的一个纠正过程。1997年在世界卫生组织发表的《埃里切宣言》成为该概念在国际上应用于传统医学体系的基础。随着阿育吠陀医学在国际上越来越被认可,监管机构为阿育吠陀医学实施了类似的项目,特别是因为一些医学专业人员、科学家和公众报告在服用阿育吠陀制剂后出现了不良反应。因此,世界卫生组织说服印度政府卫生和家庭福利部阿育吠陀、悉达和尤那尼医学部(AYUSH)实施阿育吠陀医学的药物警戒项目,以确保阿育吠陀药物的安全性和有效性。经过一年的尽职调查,该药物警戒项目于2008年9月29日在全国启动。自那时起,阿育吠陀、悉达和尤那尼药物一直根据贾姆讷格尔IPGTRA国家药物警戒资源中心编写并经AYUSH部批准的一份协议的规定进行监测。该项目于2009年1月21日首先由国家阿育吠陀、悉达和尤那尼药物药物警戒咨询委员会(NPCC - ASU)进行审查,并于2010年2月15日再次审查,当时一次评估会议实际上批准了该项目。这些会议的成果包括若干关于提高项目效率措施的建议。最近的进展包括在所有阿育吠陀教学机构和研究中心设立药物警戒中心。